DiaMedica (TSX VENTURE:DMA), is pleased to announce it has received regulatory
approval to commence an anticipated 76 subject Phase I/II clinical trial for
DM-199. The clinical trial, to be conducted in the Netherlands, is designed to
evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36
healthy volunteers and in 40 T2D patients. Data from this trial will also
support future DM-199 clinical trial regulatory filings for Type 1 and 2
diabetes and in other potential indications.


"We look forward to commencing the DM-199 clinical trial," stated Mr. Rick
Pauls, Chairman & CEO, DiaMedica. "Based on pre-clinical results showing a novel
dual mechanism of action (insulin sensitizer and insulin secretagogue) that
improves glucose control and blood pressure, we have high hopes for this drug in
improving the lives of diabetes patients."


The Phase I stage, a randomized, controlled trial to evaluate the safety,
tolerability and pharmacokinetics of DM-199 in healthy volunteers, consists of
both single ascending dose arms, and in multiple ascending dose for 14 days arms
to assess the maximum tolerable dose. In the Phase II stage, T2D patients will
initially be assessed for acute safety and efficacy in single ascending dose
study via a meal tolerance test. A follow on 28-day dosing double-blinded
placebo-controlled to assess the efficacy and safety of longer term DM-199 use.
Efficacy endpoints will include measuring HbA1c, post-meal blood glucose,
average blood glucose and glucose regulatory peptides levels over the 28-day
study period.


About DiaMedica

DiaMedica Inc. (TSX VENTURE:DMA) is a clinical stage biopharmaceutical company
focused on the discovery and development of novel therapies to treat diabetes
and the complications associated with diabetes. DiaMedica's lead compound,
DM-199, is a recombinant human protein that represents a novel approach to
treating Type 1 and Type 2 diabetes. Based on the Company's understanding of the
postprandial state, DiaMedica is also developing a novel monoclonal antibody,
DM-204 for the treatment of Type 2 diabetes. Chronic treatment with DM-204 in a
pre-clinical Type 2 diabetes model resulted in a significant improvement in
blood glucose control as measured by HbA1c and also significant improved blood
pressure and serum cholesterol levels.


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
Chairman & CEO
763-710-4455
info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more DiaMedica Inc. Charts.
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more DiaMedica Inc. Charts.